Carnegie Investment Counsel Purchases 25,146 Shares of AbbVie Inc. $ABBV

Carnegie Investment Counsel grew its position in shares of AbbVie Inc. (NYSE:ABBV) by 22.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 139,194 shares of the company’s stock after purchasing an additional 25,146 shares during the quarter. Carnegie Investment Counsel’s holdings in AbbVie were worth $32,229,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Marshall & Sullivan Inc. WA bought a new stake in AbbVie during the 2nd quarter worth approximately $25,000. Evolution Wealth Management Inc. acquired a new position in shares of AbbVie during the second quarter worth $26,000. Spurstone Advisory Services LLC bought a new stake in shares of AbbVie in the second quarter worth $28,000. Financial Gravity Companies Inc. acquired a new stake in AbbVie in the second quarter valued at $36,000. Finally, Delos Wealth Advisors LLC bought a new position in AbbVie during the 2nd quarter worth $39,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

Analyst Upgrades and Downgrades

ABBV has been the topic of a number of analyst reports. Berenberg Bank upgraded AbbVie from a “hold” rating to a “buy” rating and upped their price target for the company from $170.00 to $270.00 in a research report on Wednesday, September 17th. Cantor Fitzgerald set a $250.00 target price on AbbVie and gave the company an “overweight” rating in a report on Thursday, October 9th. Scotiabank started coverage on shares of AbbVie in a report on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 price target for the company. Evercore ISI boosted their price target on shares of AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a research report on Monday, September 22nd. Finally, JPMorgan Chase & Co. increased their price objective on shares of AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research report on Monday, November 3rd. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $245.84.

AbbVie Stock Performance

Shares of ABBV stock opened at $230.07 on Friday. The firm has a 50 day moving average of $226.73 and a 200-day moving average of $212.57. The company has a market cap of $406.63 billion, a price-to-earnings ratio of 174.30, a price-to-earnings-growth ratio of 1.31 and a beta of 0.36. The company has a quick ratio of 0.60, a current ratio of 0.72 and a debt-to-equity ratio of 44.14. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. During the same period in the prior year, the firm earned $3.00 earnings per share. AbbVie’s revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, equities analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date of this dividend is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio is presently 496.97%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.